An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA) [Estudio abierto, de múltiples brazos de tratamiento, no comparativo para evaluar la seguridad y tolerabilidad de canakinumab (ACZ885) en pacientes con artritis idiopática juvenil sistémica (AIJS) activa.]

Trial Profile

An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA) [Estudio abierto, de múltiples brazos de tratamiento, no comparativo para evaluar la seguridad y tolerabilidad de canakinumab (ACZ885) en pacientes con artritis idiopática juvenil sistémica (AIJS) activa.]

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 30 Sep 2017

At a glance

  • Drugs Canakinumab (Primary)
  • Indications Juvenile rheumatoid arthritis
  • Focus Adverse reactions; Biomarker; Pharmacogenomic; Registrational
  • Acronyms Beta-SPECIFIC-4Pa
  • Sponsors Novartis
  • Most Recent Events

    • 02 Feb 2013 Planned number of patients changed from 220 to 239 as reported by European Clinical Trials Database record.
    • 02 Feb 2013 New source identified and integrated (European Clinical Trials Database record: EudraCT2012-003054-92).
    • 24 Jan 2013 Status changed from not yet recruiting to recruiting as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top